Indeed, in the ALL IC-BFM study protocol,85 genomic alterations in PTEN have been associated with poor response to corticosteroid therapy, unfavorable clinical outcomes, and an augmented risk for relapse. The gene discussed is PTEN; the disease is acute lymphoblastic leukemia.